{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:52:44Z","timestamp":1777679564590,"version":"3.51.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Valproate-induced hyperammonemic encephalopathy (VHE) is a rare but potentially fatal complication of valproate therapy. It is characterized by elevated blood ammonia levels accompanied by central nervous system dysfunction, with clinical manifestations including varying degrees of impaired consciousness, focal neurological deficits, increased seizure frequency, respiratory abnormalities, and metabolic alkalosis. VHE is more common in patients on long-term or high-dose therapy. Although VHE has been frequently reported in neurology and psychiatry, and valproate is widely used for seizure prophylaxis in neurosurgical patients, VHE is easily misdiagnosed or overlooked in the postoperative setting due to the complex etiology of impaired consciousness (e.g., cerebral edema, cerebral infarction, delayed hemorrhage, cerebral vasospasm, seizures, brainstem injury, electrolyte disturbances, and effects of anesthetic agents). We present a case highlighting the need for vigilance regarding VHE and the timely initiation of ammonia-lowering therapy, even when isolated disturbance of consciousness occurs on the fifth postoperative day in the presence of normal liver function.<\/jats:p>","DOI":"10.3389\/fmed.2026.1769203","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:51:19Z","timestamp":1775051479000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Valproate-induced hyperammonemic encephalopathy after aneurysm clipping surgery: a case report with literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Maotang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Jiangnan University Medical Center, Jiangnan University","place":["Wuxi, China"]},{"name":"Department of Neurosurgery, Wuxi No. 2 People\u2019s Hospital","place":["Wuxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyi","family":"Sang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Jiangnan University Medical Center, Jiangnan University","place":["Wuxi, China"]},{"name":"Department of Neurosurgery, Wuxi No. 2 People\u2019s Hospital","place":["Wuxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Jiangnan University Medical Center, Jiangnan University","place":["Wuxi, China"]},{"name":"Department of Neurosurgery, Wuxi No. 2 People\u2019s Hospital","place":["Wuxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Jiangnan University Medical Center, Jiangnan University","place":["Wuxi, China"]},{"name":"Department of Neurosurgery, Wuxi No. 2 People\u2019s Hospital","place":["Wuxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40120-022-00419-8","article-title":"Effect of ANKK1 polymorphisms on serum valproic acid concentration in chinese han adult patients in the early postoperative period.","volume":"12","author":"Ma","year":"2023","journal-title":"Neurol Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s13256-025-05294-z","article-title":"Valproate-induced hyperammonemic encephalopathy: the role of clinical pharmacists in medication safety-a case report.","volume":"19","author":"Chen","year":"2025","journal-title":"J Med Case Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e76603","DOI":"10.7759\/cureus.76603","article-title":"Valproate-Induced hyperammonemic encephalopathy successfully treated with levocarnitine in an elderly patient without liver dysfunction.","volume":"16","author":"Kaneko","year":"2024","journal-title":"Cureus."},{"key":"B4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.nec.2025.03.014","article-title":"Sudden Neurologic Worsening.","volume":"36","author":"Akel","year":"2025","journal-title":"Neurosurg Clin N Am."},{"key":"B5","doi-asserted-by":"publisher","first-page":"104708","DOI":"10.5498\/wjp.v15.i4.104708","article-title":"Research progress of postoperative delirium in neurosurgery.","volume":"15","author":"Wang","year":"2025","journal-title":"World J Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s13054-023-04655-8","article-title":"The spectrum of sepsis-associated encephalopathy: a clinical perspective.","volume":"27","author":"Sonneville","year":"2023","journal-title":"Crit Care."},{"key":"B7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/practneurol-2021-003194","article-title":"Posterior reversible encephalopathy syndrome (PRES): diagnosis and management.","volume":"22","author":"Triplett","year":"2022","journal-title":"Pract Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3389\/fneur.2020.00591","article-title":"Cerebrospinal fluid hypovolemia and posterior reversible encephalopathy syndrome.","volume":"11","author":"Zheng","year":"2020","journal-title":"Front Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00655.x","article-title":"Valproate-induced hyperammonemic encephalopathy.","volume":"114","author":"Segura-Bruna","year":"2006","journal-title":"Acta Neurol Scand."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e47288","DOI":"10.7759\/cureus.47288","article-title":"Valproate-Induced hyperammonemic encephalopathy causing new-onset seizures.","volume":"15","author":"Sammar","year":"2023","journal-title":"Cureus."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e20380","DOI":"10.7759\/cureus.20380","article-title":"A case of valproic-acid induced hyperammonemic encephalopathy.","volume":"13","author":"Iqbal","year":"2021","journal-title":"Cureus."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1593","DOI":"10.7759\/cureus.1593","article-title":"Valproate-Induced hyperammonemic encephalopathy.","volume":"9","author":"Farooq","year":"2017","journal-title":"Cureus."},{"key":"B13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1023\/a:1021918104127","article-title":"Valproate-induced hyperammonemic encephalopathy.","volume":"17","author":"Verrotti","year":"2002","journal-title":"Metab Brain Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"875636","DOI":"10.3389\/fpsyt.2022.875636","article-title":"Case report: a case of valproic acid-induced hyperammonemic encephalopathy associated with the initiation of lithium: a re-duplicable finding.","volume":"13","author":"Levy","year":"2022","journal-title":"Front Psychiatry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/brainsci10030187","article-title":"Valproic acid-induced hyperammonemic encephalopathy in a patient with bipolar disorder: a case report.","volume":"10","author":"Wu","year":"2020","journal-title":"Brain Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.9740\/mhc.2024.02.028","article-title":"Valproate, risperidone, and paliperidone: a case of valproate-induced hyperammonemic encephalopathy.","volume":"14","author":"Wesselman","year":"2024","journal-title":"Ment Health Clin."},{"key":"B17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5414\/CP204673","article-title":"Valproic acid-induced hyperammonemia with encephalopathy in adults: a meta-analysis.","volume":"63","author":"Huang","year":"2025","journal-title":"Int J Clin Pharmacol Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1016\/j.wneu.2020.09.027","article-title":"Incidence, presentation, and risk factors for sodium valproate-associated hyperammonemia in neurosurgical patients: a prospective, observational study.","volume":"144","author":"Woo","year":"2020","journal-title":"World Neurosurg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s10143-024-03054-z","article-title":"Valproate-induced hyperammonemic encephalopathy in neurosurgical patients: our experience and systematic literature review.","volume":"47","author":"Kumarasamy","year":"2024","journal-title":"Neurosurg Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jhep.2010.11.031","article-title":"New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.","volume":"55","author":"Aires","year":"2011","journal-title":"J Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.7861\/clinmed.Let.23.4.1","article-title":"Valproate induced carnitine deficiency and hyperammonaemia.","volume":"23","author":"McCarron","year":"2023","journal-title":"Clin Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"116034","DOI":"10.1016\/j.bcp.2024.116034","article-title":"Mitochondrial targets in hyperammonemia: addressing urea cycle function to improve drug therapies.","volume":"222","author":"Moedas","year":"2024","journal-title":"Biochem Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2193-1801-2-13","article-title":"Valproic acid-induced hyperammonemic encephalopathy - a potentially fatal adverse drug reaction.","volume":"2","author":"Sousa","year":"2013","journal-title":"Springerplus."},{"key":"B24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.genhosppsych.2011.12.009","article-title":"Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management.","volume":"34","author":"Chopra","year":"2012","journal-title":"Gen Hosp Psychiatry."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.32255","article-title":"L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: a double-blind randomized controlled trial.","volume":"75","author":"Jain","year":"2022","journal-title":"Hepatology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"CD012410","DOI":"10.1002\/14651858.CD012410.pub2","article-title":"L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.","volume":"5","author":"Goh","year":"2018","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1769203\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:51:19Z","timestamp":1775051479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1769203\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":26,"alternative-id":["10.3389\/fmed.2026.1769203"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1769203","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1769203"}}